Targeting Cyclin-Dependent Kinases in Ovarian Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Dinh P, Harnett P, Piccart-Gebhart MJ, Awada A. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol/Hematol 2008;67(2):103–112.
   PubMed Web of Science ®Google Scholar
• Ricciardelli C, Oehler MK. Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 2009;62(3):270–275.
   PubMed Web of Science ®Google Scholar
• Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas 2014;77(2):128–136.
   PubMed Web of Science ®Google Scholar
• Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, et al. Cyclin e1 and rtk/ras signaling drive cdk inhibitor resistance via activation of e2f and ets. Oncotarget 2015;6(2):696–714.
   PubMed Web of Science ®Google Scholar
• Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol 2013;14(9):853–862.
   PubMed Web of Science ®Google Scholar
• Hirakawa H, Yokoyama Y, Yoshida H, Mizunuma H. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice. J Ovarian Res 2014;7(1):1–8.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14(2):130–146.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. Pd 0332991, a selective cyclin d kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11(5):R77.
   PubMed Web of Science ®Google Scholar
• Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al.. Eralpha-dependent e2f transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discovery 2011;1(4):338–351.
   PubMed Web of Science ®Google Scholar
• Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, et al. Therapeutically activating rb: re-establishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011;18(3):333–345.
   PubMed Web of Science ®Google Scholar
• Bell D, Berchuck A, Birrer M. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(adp-ribose) polymerase inhibitors. J Biol Chem 2014;289(13):9247–9253.
   PubMed Web of Science ®Google Scholar
• Gorodnova TV, Maksimov S, Guseinov KD, Imianitov EN. [Effectiveness of platinum-based chemotherapy in ovarian cancer patients with brca1/2 mutations]. Voprosy Onkologii 2014;60(3):339–342.
   PubMedGoogle Scholar
• Wiedemeyer WR, Beach JA, Karlan BY. Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting brca and the homologous recombination system. Front Oncol 2014;4:34.
   PubMedGoogle Scholar
• Lim S, Kaldis P. Cdks, cyclins and ckis: roles beyond cell cycle regulation. Development (Cambridge, England) 2013;140(15):3079–3093.
   PubMed Web of Science ®Google Scholar
• Malumbres M. Cyclin-dependent kinases. Genome Biol 2014;15(6):122.
   PubMed Web of Science ®Google Scholar
• Atherton-Fessler S, Parker LL, Geahlen RL, Piwnica-Worms H. Mechanisms of p34cdc2 regulation. Mol Cell Biol 1993;13(3):1675–1685.
   PubMed Web of Science ®Google Scholar
• Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: Structures of cdks, their cyclin activators, and cip and ink4 inhibitors. J Mol Biol 1999;287(5):821–828.
   PubMed Web of Science ®Google Scholar
• Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (cdks), growth suppressor genes and cyclin-dependent kinase inhibitors (ckis). Oncogene 1995;11(2):211–219.
   PubMed Web of Science ®Google Scholar
• Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, et al. Cyclin d1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 2009;23(7):1320–1328.
   PubMed Web of Science ®Google Scholar
• Peyressatre M, Prevel C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers 2015;7(1):179–237.
   PubMed Web of Science ®Google Scholar
• Johnson N, Shapiro GI. Cyclin-dependent kinases (cdks) and the DNA damage response: Rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 2010;14(11):1199–1212.
   PubMed Web of Science ®Google Scholar
• Tadesse S, Yu M, Kumarasiri M, Le BT, Wang S. Targeting cdk6 in cancer: state of the art and new insights. Cell Cycle (Georgetown, TX) 2015;14(20):3220–3230.
   PubMed Web of Science ®Google Scholar
• Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, et al. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer 1998;78(4):454–463.
   PubMed Web of Science ®Google Scholar
• Adams PD. Healing and hurting: Molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell 2009;36(1):2–14.
   PubMed Web of Science ®Google Scholar
• Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011;192(4):547–556.
   PubMed Web of Science ®Google Scholar
• Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004;23(16):2919–2933.
   PubMed Web of Science ®Google Scholar
• Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120(4):513–522.
   PubMed Web of Science ®Google Scholar
• Raghuram GV, Mishra PK. Stress-induced premature senescence: a new culprit in ovarian tumorigenesis? Indian J Med Res 2014;140(Suppl 1):S120–S129.
   PubMedGoogle Scholar
• Mikula-Pietrasik J, Sosinska P, Naumowicz E, Maksin K, Piotrowska H, Wozniak A, et al. Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo. Clin Exp Metastasis 2016;33(1):15–27
   PubMed Web of Science ®Google Scholar
• Cheng Z, Guo J, Chen L, Luo N, Yang W, Qu X. Overexpression of TMEM158 contributes to ovarian carcinogenesis. J Exp Clin Cancer Res 2015;34:75.
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81(3):323–330.
   PubMed Web of Science ®Google Scholar
• Milde-Langosch K, Riethdorf S. Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol 2003;196(2):224–244.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, et al. Expression of p16 and retinoblastoma determines response to cdk4/6 inhibition in ovarian cancer. Clin Cancer Res 2011;17(6):1591–1602.
   PubMed Web of Science ®Google Scholar
• Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, et al. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol 2011;30(3):205–217.
   PubMed Web of Science ®Google Scholar
• Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T, et al. The p16-cyclin d1/cdk4-prb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999;5(12):4152–4157.
   PubMed Web of Science ®Google Scholar
• Milde-Langosch K, Hagen M, Bamberger AM, Loning T. Expression and prognostic value of the cell-cycle regulatory proteins, rb, p16mts1, p21waf1, p27kip1, cyclin e, and cyclin d2, in ovarian cancer. Int J Gynecol Pathol 2003;22(2):168–174.
   PubMed Web of Science ®Google Scholar
• Schmider-Ross A, Pirsig O, Gottschalk E, Denkert C, Lichtenegger W, Reles A. Cyclin-dependent kinase inhibitors cip1 (p21) and kip1 (p27) in ovarian cancer. J Cancer Res Clin Oncol 2006;132(3):163–170.
   PubMed Web of Science ®Google Scholar
• Xu L, Cai J, Yang Q, Ding H, Wu L, Li T, et al. Prognostic significance of several biomarkers in epithelial ovarian cancer: A meta-analysis of published studies. J Cancer Res Clin Oncol 2013;139(8):1257–1277.
   PubMed Web of Science ®Google Scholar
• Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin d1, p53, and p21waf1/cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004;10(15):5168–5177.
   PubMed Web of Science ®Google Scholar
• Felix AS, Sherman ME, Hewitt SM, Gunja MZ, Yang HP, Cora RL, et al. Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers. Front Oncol 2015;5:25.
   PubMed Web of Science ®Google Scholar
• Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (gog158) and an update on gog0182-icon5. Int J Gynecol Cancer 2003;13(Suppl 2):149–155.
   PubMed Web of Science ®Google Scholar
• Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H. Receptor tyrosine kinase (rtk) inhibition is effective in chemosensitising egfr-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol 2006;72(8):941–948.
   PubMed Web of Science ®Google Scholar
• Coley HM, Safuwan NA, Chivers P, Papacharalbous E, Giannopoulos T, Butler-Manuel S, et al. The cyclin-dependent kinase inhibitor p57(kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the cdk inhibitor seliciclib in ovarian cancer. Brit J Cancer 2012;106(3):482–489.
   PubMed Web of Science ®Google Scholar
• Caldon CE, Musgrove EA. Distinct and redundant functions of cyclin e1 and cyclin e2 in development and cancer. Cell Division 2010;5:2.
   PubMed Web of Science ®Google Scholar
• Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, et al. Resistance to cdk2 inhibitors is associated with selection of polyploid cells in ccne1-amplified ovarian cancer. Clin Cancer Res 2013;19(21):5960–5971.
   PubMed Web of Science ®Google Scholar
• Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, et al.. Cyclin e expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 2006;106(9):1925–1932.
   PubMed Web of Science ®Google Scholar
• Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, et al. Cyclin e1 (ccne1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – a study of the ovcad consortium. Eur J Cancer 2014;50(1):99–110.
   PubMed Web of Science ®Google Scholar
• Blazek D, Kohoutek J, Bartholomeeusen K, Johansen E, Hulinkova P, Luo Z, et al. The cyclin k/CDK12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 2011;25(20):2158–2172.
   PubMed Web of Science ®Google Scholar
• Ekumi KM, Paculova H, Lenasi T, Pospichalova V, Bosken CA, Rybarikova J, et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the CDK12/cyck complex. Nucleic Acids Res 2015;43(5):2575–2589.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng K, Gong K, Fu AK, Ip NY. Pctaire1 phosphorylates n-ethylmaleimide-sensitive fusion protein: implications in the regulation of its hexamerization and exocytosis. J Biol Chem 2006;281(15):9852–9858.
   PubMed Web of Science ®Google Scholar
• Mikolcevic P, Sigl R, Rauch V, Hess MW, Pfaller K, Barisic M, et al. Cyclin-dependent kinase 16/pctaire kinase 1 is activated by cyclin y and is essential for spermatogenesis. Mol Cell Biol 2012;32(4):868–879.
   PubMed Web of Science ®Google Scholar
• Duan HF, Li XQ, Hu HY, Li YC, Cai Z, Mei XS, et al. Functional elucidation of mir-494 in the tumorigenesis of nasopharyngeal carcinoma. Tumour Biol 2015;36(9):6679–6689.
   PubMed Web of Science ®Google Scholar
• Endicott JA, Noble ME. Structural characterization of the cyclin-dependent protein kinase family. Biochem Soc Trans 2013;41(4):1008–1016.
   PubMed Web of Science ®Google Scholar
• Yanagi T, Krajewska M, Matsuzawa S, Reed JC. Pctaire1 phosphorylates p27 and regulates mitosis in cancer cells. Cancer Res 2014;74(20):5795–5807.
   PubMed Web of Science ®Google Scholar
• Yanagi T, Shi R, Aza-Blanc P, Reed JC, Matsuzawa S. Pctaire1-knockdown sensitizes cancer cells to tnf family cytokines. PloS One 2015;10(3): e0119404.
   Web of Science ®Google Scholar
• Zhou QY, Y. Upregulated CDK16 expression in serous epithelial ovarian cancer cells. Med Sci Monit 2015; 21:3409–3414.
   PubMed Web of Science ®Google Scholar
• Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, et al. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of pha-793887, a potent cdk inhibitor suitable for intravenous dosing. Bioorg Med Chem 2010;18(5):1844–1853.
   PubMed Web of Science ®Google Scholar
• Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, et al. A first in man, phase i dose-escalation study of pha-793887, an inhibitor of multiple cyclin-dependent kinases (cdk2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle (Georgetown, TX) 2011;10(6):963–970.
   PubMed Web of Science ®Google Scholar
• Liu MC, Lin TS, Sartorelli AC. Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 1992;35(20):3672–3677.
   PubMed Web of Science ®Google Scholar
• Lin ZP. Triapine disrupts ctip-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res 2014;12(3):381–393.
   Google Scholar
• Walsby E, Pratt G, Shao H, Abbas AY, Fischer PM, Bradshaw TD, et al. A novel cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget 2014;5(2):375–385.
   PubMed Web of Science ®Google Scholar
• Lam F, Abbas AY, Shao H, Teo T, Adams J, Li P, et al. Targeting rna transcription and translation in ovarian cancer cells with pharmacological inhibitor cdki-73. Oncotarget 2014;5(17):7691–7704.
   PubMed Web of Science ®Google Scholar
• Liu X, Lam F, Shi S, Fischer PM, Wang S. in vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor cdki-83. Invest New Drugs 2012;30(3):889–897.
   PubMed Web of Science ®Google Scholar
• Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. Dinaciclib (sch 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010;9(8):2344–2353.
   PubMed Web of Science ®Google Scholar
• Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 2015;29(7):1524–1529.
   PubMed Web of Science ®Google Scholar
• Chen XX, Xie FF, Zhu XJ, Lin F, Pan SS, Gong LH, et al. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. Oncotarget 2015;6(17):14926–14939.
   PubMed Web of Science ®Google Scholar
• Kaminsky R, Ducray P, Jung M, Clover R, Rufener L, Bouvier J, et al. A new class of anthelmintics effective against drug-resistant nematodes. Nature 2008;452(7184):176–180.
   PubMed Web of Science ®Google Scholar
• Bahrami F, Morris DL, Rufener L, Pourgholami MH. Anticancer properties of novel aminoacetonitrile derivative monepantel (add 1566) in pre-clinical models of human ovarian cancer. Am J Cancer Res 2014;4(5):545–557.
   PubMed Web of Science ®Google Scholar
• McCain J. First-in-class cdk4/6 inhibitor palbociclib could usher in a new wave of combination therapies for hr+, her2− breast cancer. P & T 2015;40(8):511–520.
   PubMedGoogle Scholar
• Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor pd 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18(2):568–576.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. New England J Med 2015;373(3):209–219.
   PubMed Web of Science ®Google Scholar
• Senderowicz AM. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999;17(3):313–320.
   PubMed Web of Science ®Google Scholar
• Song Y, Xin X, Zhai X, Xia Z, Shen K. Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified htert promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. J Ovarian Res 2014;7:121.
   PubMed Web of Science ®Google Scholar
• Song Y, Xin X, Zhai X, Xia Z, Shen K. Sequential combination of flavopiridol with taxol synergistically suppresses human ovarian carcinoma growth. Arch Gynecol Obst 2015;291(1):143–150.
   PubMed Web of Science ®Google Scholar
• Bible KC, Peethambaram PP, Oberg AL, Maples W, Groteluschen DL, Boente M, et al. A phase 2 trial of flavopiridol (alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: Mc0261. Gynecol Oncol 2012;127(1):55–62.
   PubMed Web of Science ®Google Scholar
• He F, Wu HN, Cai MY, Li CP, Zhang X, Wan Q, et al. Inhibition of ovarian cancer cell proliferation by pien tze huang via the akt-mtor pathway. Oncol Lett 2014;7(6):2047–2052.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Xu YL, Tang ZH, Xu XH, Chen X, Li T, et al. Effects of alisol b 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest, apoptosis, migration and invasion inhibition. Phytomed 2016;23(8):800–809.
   PubMed Web of Science ®Google Scholar
• Liu KC, Lin MT, Lee SS, Chiou JF, Ren S, Lien EJ. Antiviral tannins from two phyllanthus species. Planta Medica 1999;65(1):43–46.
   PubMed Web of Science ®Google Scholar
• Hau DK, Zhu GY, Leung AK, Wong RS, Cheng GY, Lai PB, et al. in vivo anti-tumour activity of corilagin on hep3b hepatocellular carcinoma. Phytomed 2010;18(1):11–15.
   PubMed Web of Science ®Google Scholar
• Jia L, Jin H, Zhou J, Chen L, Lu Y, Ming Y, et al. A potential anti-tumor herbal medicine, corilagin, inhibits ovarian cancer cell growth through blocking the tgf-beta signaling pathways. BMC Complem Altern Med 2013;13:33.
   PubMed Web of Science ®Google Scholar
• Kavandi L, Lee LR, Bokhari AA, Pirog JE, Jiang Y, Ahmad KA, et al. The Chinese herbs scutellaria baicalensis and fritillaria cirrhosa target nfkappab to inhibit proliferation of ovarian and endometrial cancer cells. Mol Carcinog 2015;54(5):368–378.
   PubMed Web of Science ®Google Scholar
• Spagnuolo C, Russo GL, Orhan IE, Habtemariam S, Daglia M, Sureda A, et al. Genistein and cancer: current status, challenges, and future directions. Adv Nutr (Bethesda, MD) 2015;6(4):408–419.
   PubMed Web of Science ®Google Scholar
• Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of p21waf1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 1998;32(3):123–131.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim HS, Song YS. Genistein as a potential anticancer agent against ovarian cancer. J Tradit Complem Med 2012;2(2):96–104.
   PubMedGoogle Scholar